We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$89.4M
Cap. Flow %
4.5%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Consumer Staples 0.19%
3 Consumer Discretionary 0.06%
4 Energy 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
51
PUT
DELISTED
Radius Health, Inc.
RDUS
$9.05M 0.46%
200,000
+190,200
+1,941% +$7.27M
SNDA icon
52
Sonida Senior Living
SNDA
$1.94B
$8.06M 0.41%
35,345
-3,000
-8% -$648K
TLPH icon
53
Talphera
TLPH
$64.4M
$8.02M 0.4%
186,567
-83,869
-31% -$4.26M
EGRX
54
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$7.89M 0.4%
+100,000
New +$8.18M
CRBP icon
55
Corbus Pharmaceuticals
CRBP
$220M
$7.76M 0.39%
41,083
-584
-1% -$115K
SIOX
56
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.96M 0.35%
37,500
+12,500
+50% +$2.19M
QURE icon
57
uniQure
QURE
$3.48B
$6.75M 0.34%
1,090,119
-175,844
-14% -$950K
VIVE
58
DELISTED
VIVEVE MED INC
VIVE
$6.39M 0.32%
890
-49
-5% -$365K
RARE icon
59
CALL
Ultragenyx Pharmaceutical
RARE
$2.58B
$6.21M 0.31%
+100,000
New +$6.02M
NVTA
60
DELISTED
Invitae Corporation
NVTA
$6.21M 0.31%
649,500
+169,500
+35% +$1.67M
ZYME icon
61
Zymeworks
ZYME
$2.1B
$6.1M 0.31%
+730,768
New +$8.18M
ANIP icon
62
ANI Pharmaceuticals
ANIP
$1.72B
$5.87M 0.3%
125,399
-129,490
-51% -$6.25M
CLSD
63
DELISTED
Clearside Biomedical
CLSD
$5.65M 0.28%
41,345
-6,126
-13% -$736K
UNH icon
64
UnitedHealth
UNH
$361B
$5.28M 0.27%
28,480
+15,480
+119% +$2.71M
FOMX
65
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.18M 0.26%
1,117,324
-205,670
-16% -$918K
URGN icon
66
UroGen Pharma
URGN
$2.25B
$4.86M 0.24%
+269,014
New +$4.67M
ABEOW
67
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$4.29M 0.22%
1,259,636
– –
SRRA
68
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.28M 0.22%
91,380
-1,213
-1% -$61.9K
FWP
69
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$3.96M 0.2%
27,817
-22,789
-45% -$3.17M
NEPT
70
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$3.8M 0.19%
4,657
– –
EXAS
71
DELISTED
Exact Sciences
EXAS
$3.54M 0.18%
100,000
-310,000
-76% -$9.57M
PFNX
72
DELISTED
Pfenex Inc.
PFNX
$3.39M 0.17%
845,973
-46,874
-5% -$216K
OCGN icon
73
Ocugen
OCGN
$471M
$3.18M 0.16%
29,630
– –
BHVN
74
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3M 0.15%
+120,000
New +$2.76M
ADMA icon
75
ADMA Biologics
ADMA
$2.14B
$2.77M 0.14%
721,102
– –
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $89.4M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.